Lantheus: 'Supplier Diversification' Strategy After Ben Venue Shutdown

By Dan Stanton

- Last updated on GMT

Related tags: Ben venue, New drug application

FDA approve new site for ultrasound contrast agent manufacture
FDA approve new site for ultrasound contrast agent manufacture
The US FDA has expedited approval of Jubilant HollisterStier manufacturing sites in further fallout from Ben Venue’s consent decree.

Jubilant HollisterStier’s (JHS) manufacturing facilities in Washington and Maryland will become the focus for the manufacturing of Definity and two other pharmaceutical agents used in nuclear medicine imaging as developer Lantheus Medical Imaging moves away from Ben Venue Laboratories.

Last month’ consent decree​ limited manufacturing​ at Ben Venue Laboratories' plant in Bedford Ohio and caused customers to search for alternative solutions.

Lantheus spokeswoman Meara Murphy told that “supplier diversification for our core products is a key priority”​ as operations are transitioned away from Ben Venue.

Murphy said that manufacture of Definity would continue at Ben Venue until the end of the year to ensure full product supply and a smooth transition to both JHS and a potential additional supplier who Lantheus is in the process of procuring.

Definity is an ultrasound contrast agent designed to enhance image quality and clarity of the ventricular chamber in echocardiograms, reducing suboptimal images – an image where at least 2 out of 6 myocardial segments of the left ventricle cannot be visualized in the apical views.

Quality Assured After Definity Shortages

In 2012, Definity was in short supply and was even out of stock for a short time following the shutdown at Ben Venue’s plant​. It was listed on the FDA’s Drug Shortage Index and prompted Lantheus to hunt for new suppliers such as JHS.

“We worked closely with the FDA to expedite the review process of our Supplemental New Drug Application that allows JHS to be a new manufacturing site for Definity,”​ said Murphy.

She added: “We have in place a stringent and comprehensive Contract Manufacturing Organization (CMO) program, which includes quality controls and release standards that ensure our products are compliant and safe.”

Other companies have been forced to rethink their manufacturing options following shortages of key products during Ben Venue’s turbulent times. Doxil, the ovarian cancer drug, suffered badly and recently the drug’s marketer - J&J’s Janssen – was forced to locate alternative manufacturing​ avenues.

The FDA has also proved itself to be proactive as expediting approval of alternative facilities and options, such as Sun Pharma’s Doxil equivalent​ and JHS’s facilities, demonstrating a determination to avoid future shortages in light of Ben Venue’s problems.

Related news

Show more

Related products

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more